Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
出版年份 2013 全文链接
标题
Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 11, Pages 1411-1423
出版商
Informa Healthcare
发表日期
2013-07-26
DOI
10.1517/13543784.2013.822485
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease
- (2013) Gilbert R. Thompson ATHEROSCLEROSIS SUPPLEMENTS
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
- (2013) Todd J. Anderson et al. CANADIAN JOURNAL OF CARDIOLOGY
- PCSK9 inhibitors
- (2013) Michel Farnier CURRENT OPINION IN LIPIDOLOGY
- Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
- (2013) Nabil G. Seidah CURRENT PHARMACEUTICAL DESIGN
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
- (2013) et al. EUROPEAN HEART JOURNAL
- HDL—is it too big to fail?
- (2013) Dominic S. Ng et al. Nature Reviews Endocrinology
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
- (2012) Jennifer G. Robinson et al. AMERICAN JOURNAL OF CARDIOLOGY
- Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis
- (2012) Mark Lemstra et al. CANADIAN JOURNAL OF CARDIOLOGY
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Anti-PCSK9 therapies for the treatment of hypercholesterolemia
- (2012) Amanda J Hooper et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
- (2012) S. Matthijs Boekholdt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibodies: magic bullets with a hefty price tag
- (2012) A. F. Shaughnessy BMJ-British Medical Journal
- Adherence to Statin Therapy in Elderly Patients After Hospitalization for Coronary Revascularization
- (2011) Alexander Kulik et al. AMERICAN JOURNAL OF CARDIOLOGY
- ESC/EAS Guidelines for the management of dyslipidaemias
- (2011) Alberico L. Catapano et al. ATHEROSCLEROSIS
- Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)
- (2011) Shaun G. Goodman et al. CANADIAN JOURNAL OF CARDIOLOGY
- Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
- (2011) L. A. Leiter et al. DIABETIC MEDICINE
- Mipomersen, an antisense apolipoprotein B synthesis inhibitor
- (2011) Damon A Bell et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
- (2011) Anne C. Goldberg et al. Journal of Clinical Lipidology
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to biologic DMARD therapies in rheumatoid arthritis
- (2010) Tamas Koncz et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels
- (2009) Chiang-Ching Huang et al. Circulation-Cardiovascular Genetics
- Microsomal triglyceride transfer protein inhibition–friend or foe?
- (2008) Tisha R Joy et al. Nature clinical practice. Cardiovascular medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started